A clinical trial listing dated July 23, 2026 registered a new study involving carbetocin. The trial is titled "The Efficacy of Carbitocin in Reduction of Blood Loss During Myomectomy."
The study is registered under identifier NCT07721623. It is listed as Early Phase 1. Current status is not yet recruiting, according to the registry entry.
Carbetocin remains classified as an unapproved research compound. No participants have been enrolled at this stage, and no results have been posted.
This registration reflects only the planned scope of the trial as described in the listing. The title indicates the study intends to examine blood loss during myomectomy procedures, but no outcome data, efficacy claims, or safety findings are available yet. Further updates will depend on future changes to the trial's status as it moves toward recruitment and beyond.
Readers interested in background on this compound can consult the compound overview for additional context.